Treatment of Secondary Mitral Regurgitation in Heart Failure: A Shifting Paradigm in the Wake of the COAPT Trial.

Although concerns have been raised by Mitra.FR investigators about baseline differences in use of renin–angiotensin–aldosterone inhibitors among COAPT-enrolled patients, which were marginally significant by chance, a multivariable analysis published in the original COAPT manuscript demonstrated that the point estimates for benefit were similar after accounting for this consideration.[ 12 , 16 ] Similarly, while Mitra.FR investigators have expressed concerns about potential differences in baseline h

also in 26,082 other papers